Interestingly, with respect to tumours of mixed or pure oligodendrocytic lineage, alterations in p53 expression may also portend a less favourable prognosis in the clinical setting (Soini et al, 1994; Korkolopoulou et al, 1997; Miettinen et al, 2001). The gene discussed is TP53; the disease is neoplasm.